Analysts Set Clearside Biomedical, Inc. (NASDAQ:CLSD) PT at $5.33

Shares of Clearside Biomedical, Inc. (NASDAQ:CLSD) have earned a consensus rating of “Buy” from the six brokerages that are covering the firm, MarketBeat reports. Six research analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have covered the stock in the last year is $5.33.

CLSD has been the subject of several research reports. Chardan Capital reissued a “buy” rating and issued a $6.00 price objective on shares of Clearside Biomedical in a research report on Friday, November 15th. StockNews.com raised shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a research note on Thursday, December 12th. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Clearside Biomedical in a research note on Thursday. Finally, Needham & Company LLC restated a “buy” rating and set a $6.00 price objective on shares of Clearside Biomedical in a report on Thursday.

Clearside Biomedical Stock Performance

Shares of NASDAQ:CLSD opened at $0.98 on Friday. Clearside Biomedical has a 1-year low of $0.77 and a 1-year high of $2.12. The stock has a market capitalization of $74.03 million, a price-to-earnings ratio of -2.17 and a beta of 2.10. The company has a 50 day moving average price of $0.96 and a 200 day moving average price of $1.06.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of CLSD. Geode Capital Management LLC grew its holdings in shares of Clearside Biomedical by 4.5% in the fourth quarter. Geode Capital Management LLC now owns 764,058 shares of the company’s stock worth $726,000 after acquiring an additional 32,672 shares during the period. Northern Trust Corp raised its stake in shares of Clearside Biomedical by 24.0% in the fourth quarter. Northern Trust Corp now owns 165,499 shares of the company’s stock worth $157,000 after buying an additional 32,048 shares during the period. Johnson & Johnson purchased a new position in shares of Clearside Biomedical during the 3rd quarter valued at about $105,000. Finally, Investor s Fiduciary Advisor Network LLC purchased a new position in shares of Clearside Biomedical during the 4th quarter valued at about $32,000. 18.75% of the stock is owned by hedge funds and other institutional investors.

About Clearside Biomedical

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.